| Name |
|---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is...
Benzinga Rankings give you vital metrics on any stock – anytime.
You can purchase shares of Travere Therapeutics (NASDAQ:TVTX) through any online brokerage.
Other companies in Travere Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Travere Therapeutics has a consensus price target of $50.22.
The stock price for Travere Therapeutics (NASDAQ: TVTX) is $49.6 last updated October 16, 2026 at 4:00 PM EDT.
There are no upcoming dividends for Travere Therapeutics.
Travere Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Travere Therapeutics.
Travere Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
